Mayo Clinic | Strategic Alliance Partners

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.

Jeremy C. Jones, MD, discusses the clinical utility of pembrolizumab in microsatellite instability–high colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.

Daniel H. Ahn, DO, discusses the utility of atezolizumab in combination with bevacizumab in hepatocellular carcinoma.

Jeremy C. Jones, MD, discusses the importance of testing for microsatellite instability high in colorectal cancer.

Sikander Ailawadhi, MD, discusses the rationale to evaluate lisaftoclax in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.

Joleen M. Hubbard, MD, discusses the potential for treatment with immunotherapy alone in patients with colorectal cancer.

Stephen M. Ansell, MD, PhD, discusses challenges with positron emission tomography scans in patients with Hodgkin lymphoma.

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.

The National Comprehensive Cancer Network guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommended therapies for patients.

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

Donald W. Northfelt, MD, MS, FACP, discusses the progress made with CDK4/6 inhibitors in the treatment of patients with ER-expressing breast cancer and pivotal trials that have moved the needle forward.

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

Yttrium-90 glass microspheres administered in a personalized, dosimetric approach demonstrated a 16-month improvement in overall survival compared with a standard dosimetric approach in patients with unresectable hepatocellular carcinoma.

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

Tanios S. Bekaii-Saab, MD, FACP, shares his approach for treating patients with HCC across several lines of therapy, as well as factors to consider when making sequencing decisions.

Joleen M. Hubbard, MD, discusses identifying disease progression in patients with colorectal cancer.

Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.

Yi Lin, MD, PhD, discusses promising data with CAR T-cell therapy in multiple myeloma.

Rafael Fonseca, MD, discusses several clinical trials that support the use of quadruplet regimens in myeloma, the utilization of MRD in clinical decision-making, and future directions for research.

Sikander Ailawadhi, MD, discusses the future of relapsed/refractory multiple myeloma, the potential for retreatment with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, and the promise of T-cell engagers in the field.

Yttrium-90 glass microspheres, a personalized radiotherapeutic cancer treatment, induced an overall response rate of 72.2% per blinded independent central review as neoadjuvant or stand-alone treatment in 143 evaluable patients with unresectable hepatocellular carcinoma.

Kabir Mody, MD, discusses the unique approach used to deliver Y-90 glass microspheres to patients with unresectable hepatocellular carcinoma.

Shaji K. Kumar, MD, discusses treatment selection considerations in multiple myeloma.

January 27, 2021 - The combination of the polo-like kinase 1 inhibitor, onvansertib, with FOLFIRI and bevacizumab was found to have preliminary activity and favorable tolerability when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.